In the present research work, a novel capsule-in-capsule technology for biphasic delivery of Glimepiride was developed for the Diabetic patient to the best of our knowledge very less information is available on this type of formulations. The advantages of fast releasing liquid-filled-capsules and slow release tablet-filled-capsule were combined to meet the optimized requirements of our biphasic drug delivery system. Glimepiride slow releasing tablet were prepared by direct compression method and were filled into a smaller capsule. Glimepiride fast releasing liquid was prepared using olive oil and drug. This fast releasing liquid and slow releasing tablet-filledcapsule was further inserted into a bigger capsule body and closed with the cap. The various formulation batches were subjected to physicochemical studies. Drug content, in vitro drug release and stability studies. Interaction studies reveal that there was no interaction between drug and excipient employed in this study. The optimized capsule-in-capsule formulation released 21.01% of drug at the end 30min and 97.23% of drug at the end of 12hr. The drug release profile of Glimepiride capsule-in-capsule formulation fits well with higuchi model followed by zero order, First order and korsmeyer- Peppas model analysis. The stability study results indicate that the various parameters of our optimized formulation are not affected on storage at 450c/75%RH upto 6 month.
